



ASX ANNOUNCEMENT

27 November 2020

NOTICE GIVEN UNDER SECTION 708A(5)(e) OF CORPORATIONS ACT

27 November 2020: Cann Group Limited (**Cann**) (ASX: CAN) gives notice under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**) that:

- (a) Cann has on 27 November 2020 issued 75,000 fully paid ordinary shares by way of a placement to Commonwealth Scientific and Industrial Research Organisation (**CSIRO**), a sophisticated investor, as part settlement of two invoices for services rendered, without disclosure to the investor under Part 6D.2 of the *Corporations Act*; and
- (b) (c) as at the date of this notice:
 - (1) Cann has complied with the provisions of Chapter 2M of the *Corporations Act* as they apply to Cann;
 - (2) Cann has complied with section 674 of the *Corporations Act*; and
 - (3) there is no information that is “excluded information” within the meaning of sections 708A(7) and 708A(8) of the *Corporations Act* that is required to be set out in this notice under section 708A(6)(e) of the *Corporations Act*.

Authorised for release by Geraldine Farrell, Company Secretary, Cann Group Limited.

For further information please contact:

Peter Crock
CEO
Cann Group Limited
+61 3 9095 7088

contact@canngrouponlimited.com

Clive Fanning
Head of Investor Relations
Cann Group Limited
+61 3 9095 7088

clive.fanning@canngrouponlimited.com

Matthew Wright
NWR Communications
+61 451 896 420
matt@nwrcommunications.com.au

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is building a world-class business focused on breeding, cultivating, manufacturing and supplying medicinal cannabis for sale and use within Australia and for approved overseas export markets. The company has established research and cultivation facilities in Melbourne and is developing a state-of-the-art cultivation facility near Mildura, Victoria. Cann Group has executed collaboration agreements that have enabled it to establish a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. The Company is commercialising a range of imported and locally sourced and manufactured medicinal cannabis products. **Learn more about Cann Group at www.canngrouponlimited.com**